American Journal of Transplantation· 2012Q1

Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation

Lutz Liefeldt, Susanne Brakemeier, Petra Glander, Johannes Waiser et al.

240citations
Q1SCImago
2012year

Short summary

Everolimus-based immunosuppression increased the risk of developing donor-specific HLA antibodies (DSA) and antibody-mediated rejection (AMR) by 2.1 times compared to cyclosporine in kidney transplant patients (23.0% vs. 10.8%).

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Transplantation

TransplantationMedicine